TAPBPR Antibody (1059329) [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: Flow
• Clone: 1059329
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 594

TAPBPR Antibody (1059329) [Alexa Fluor® 594] Summary

• Immunogen: Chinese Hamster Ovary cell line, CHO-derived human TAPBPR
  Ala19-Arg404
  Accession # Q9BX59.2
• Specificity: Dectects human TAPBPR in direct ELISA.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TAPBPR Antibody (1059329) [Alexa Fluor® 594]

• FLJ10143
• TAP binding protein-like
• Tapasin Related Protein/TAPBPR
• Tapasin-like
• TAPASIN-R
• tapasin-related protein
• TAP-binding protein-like
• TAP-binding protein-related protein
• TAPBPL
• TAPBPR
• TAPBP-RTAP binding protein related
• TAPBPRtapasin-like

Background

TAP-binding protein-like (TAPBPL), also known as TAP binding protein-related (TAPBPR) and Tapasin-related protein (TAPASINR) is a transmembrane protein of the Immunoglobulin (Ig) superfamily (1, 2). TAPBPR was originally isolated as a homologue to TAPASIN but more recently was identified as a novel B7 family-related molecule since it shares sequence, structural, and functional similarities to B7 family members (3). Mature human TAPBPR consists of a lumenal domain containing an IgV and IgC domain, a transmembrane domain, and a cytoplasmic tail which lacks an ER retention motif. Within the lumenal domain, mature human TAPBPR shares 70% and 71% amino acid sequence identity with mouse and rat TAPBPR, respectively. Multiple alternatively spliced TAPBPR isoforms are known to exist with unique properties (4).TAPBPR is widely expressed and, similar to TAPASIN, functions as a both a chaperone protein and peptide editor of MHC class I, but in a peptide‑loading complex (PLC) independent manner (5, 6). TAPBPR decreases the rate at which MHC class I molecules mature through the secretory pathway, a role which could be important for peptide selection by MHC class I molecules (7). TAPBPR is also expressed on the surface of T cells and antigen-presenting cells (APCs) and plays an inhibitory role in the proliferation and activation of T cells (4). TAPBPR can be expressed on various cancer cells like leukemia and has the potential to be used in the treatment of autoimmune diseases and transplant rejection, as well as cancer (4).

1. Hermann, C. et al. (2015) Tissue antigens 85(3):155.
2. Teng, M. et al. (2002) European Journal of Immunology 32:1059.
3. Lin, Y. et al. (2021). EMBO Mol Med. 13(5):13404.
4. Porter, K.M. et al. (2014) Immunology 142:289.
5. Margulies, D. et al. (2020) Current Opinion in Immunology 64:71.
6. Boyle, L.H. et al. (2013) PNAS 110:3465.
7. Hermann, C. et al. (2013) Journal of Immunology 191(11):5743.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q9BX59.2()